AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA

Methods for treating glaucoma and/or Fas ligand-dependent inflammatory conditions in a subject using soluble Fas ligand (sFasL) or a fragment thereof, which may be rAAV-mediated delivery of sFasL or a fragment thereof to a subject.

Saved in:
Bibliographic Details
Main Authors Gregory-Ksander, Meredith, Ksander, Bruce, Marshak-Rothstein, Ann
Format Patent
LanguageEnglish
Published 08.08.2019
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Methods for treating glaucoma and/or Fas ligand-dependent inflammatory conditions in a subject using soluble Fas ligand (sFasL) or a fragment thereof, which may be rAAV-mediated delivery of sFasL or a fragment thereof to a subject.
Bibliography:Application Number: US201716315362